Frontiers in immunology · 2026
Impact of ALC Nadir and EDRIC on survival outcomes in limited-stage small cell lung cancer receiving chemoradiotherapy: a retrospective analysis comparing twice-daily and once-daily radiotherapy.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yao Jinquan, Li Yikun, Geng Yuxin, Xu Junhao, Sun Qixin, Huang Baiyang, Zou Bingwen, Sun Xiao, Tang Ning, Teng Feifei
Аннотация
BACKGROUND: This study aimed to evaluate the prognostic value of absolute lymphocyte count (ALC) nadir and estimated dose of radiation to immune cells (EDRIC) in patients with limited-stage small cell lung cancer (LS-SCLC).
METHODS: This study analyzed 288 patients with LS-SCLC treated with chemoradiotherapy (CRT) between 2019 and 2023. ALC nadir and EDRIC were evaluated for prognostic value across patients receiving twice-daily (BID) and once-daily (QD) radiotherapy. Survival outcomes included overall survival (OS), progression-free survival (PFS), and brain metastasis-free survival (BMFS).
RESULTS: Despite lower lymphocyte counts during early treatment in the BID group, the ALC nadir was significantly higher in the BID group compared with the QD group (median ALC nadir: 0.60 × 109/L vs. 0.49 × 109/L, P < 0.001). In the BID group, patients with ALC nadir > 0.55 × 109/L showed significantly longer OS (median OS: NR vs. 46.7 months, P = 0.011), PFS (P = 0.022), and BMFS (P = 0.013) compared with those with ALC nadir ≤ 0.55 × 109/L. Patients in the high EDRIC group had significantly shorter PFS (P = 0.001) and BMFS (P = 0.003), and a trend toward shorter OS (P = 0.179). In the QD group, no significant differences were observed when stratified by ALC nadir or EDRIC (P > 0.05).
CONCLUSION: ALC nadir and EDRIC demonstrated prognostic significance in the BID group but not in the QD group, suggesting potential differences in radiation-associated immune effects between fractionation schedules.
METHODS: This study analyzed 288 patients with LS-SCLC treated with chemoradiotherapy (CRT) between 2019 and 2023. ALC nadir and EDRIC were evaluated for prognostic value across patients receiving twice-daily (BID) and once-daily (QD) radiotherapy. Survival outcomes included overall survival (OS), progression-free survival (PFS), and brain metastasis-free survival (BMFS).
RESULTS: Despite lower lymphocyte counts during early treatment in the BID group, the ALC nadir was significantly higher in the BID group compared with the QD group (median ALC nadir: 0.60 × 109/L vs. 0.49 × 109/L, P < 0.001). In the BID group, patients with ALC nadir > 0.55 × 109/L showed significantly longer OS (median OS: NR vs. 46.7 months, P = 0.011), PFS (P = 0.022), and BMFS (P = 0.013) compared with those with ALC nadir ≤ 0.55 × 109/L. Patients in the high EDRIC group had significantly shorter PFS (P = 0.001) and BMFS (P = 0.003), and a trend toward shorter OS (P = 0.179). In the QD group, no significant differences were observed when stratified by ALC nadir or EDRIC (P > 0.05).
CONCLUSION: ALC nadir and EDRIC demonstrated prognostic significance in the BID group but not in the QD group, suggesting potential differences in radiation-associated immune effects between fractionation schedules.